On Monday, Following U.S. Stocks were among the “Top Gainers“:Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Thermo Fisher Scientific Inc (NYSE:TMO), RXi Pharmaceuticals Corp (NASDAQ:RXII), Skyworks Solutions Inc (NASDAQ:SWKS)
Synergy Pharmaceuticals Inc (NASDAQ:SGYP)’s shares picked up 4.51%, and closed at $3.71. The stock volatility for the week is 8.23%, while for the month remained 5.72%. The company holds consensus target price of $7.90.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.91 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -14.10% and Annual EPS growth for the past 5 years is considered as -6.60%.
The mean recommendation of analysts for this stock is 1.80. (where 1=Buy, 5=Sale).
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, in addition to is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Thermo Fisher Scientific Inc (NYSE:TMO), raised 4.36%, and closed at $132.97, hitting new 52-week high of $133.00. The stock has price to sale ratio of 3.12, however, price to book ratio is 2.59. With recent incline, the year-to-date (YTD) performance reflected a 6.26% gain below last year. During the past month the stocks gain 4.97%, bringing three-month performance to 5.06% and six-month performance to 8.11%. The mean recommendation of analysts for this stock is 2.20. (where 1=Buy, 5=Sale).
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables used in biological and medical research, discovery, and production of new drugs and vaccines, in addition to diagnosis of diseases. This segment serves pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for applications in the laboratory, on the production line, and in the field.
RXi Pharmaceuticals Corp (NASDAQ:RXII), enhanced 4.35%, and closed at $1.20. The company holds the market capitalization of 24.30M. For the last twelve months, the stock was able to keep return on equity at -585.30%, while return on assets at -109.20%, in response to its return on investment at -720.70%. Its 20-day moving average gained 1.82%, below 50-day moving average of -4.41%, below 200-day moving average of -42.21% from the latest market price of $1.20. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company’s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages comprise products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Skyworks Solutions Inc (NASDAQ:SWKS), rose 4.15%, and closed at $96.78, hitting new 52-week high of $96.86. The stock has the beta value of 1.22, and its volatility for the week is 2.36%, while for the month it is 2.35%. The company has the market capitalization of $17.73B. The company holds the book value per share of 14.36, whereas cash per share is 5.50. Price to book ratio remained 6.74, while price to sale ratio is 7.13. Analysts mean recommendation for the stock is said to be 1.80 (where 1=Buy, 5=sale).
Skyworks Solutions, Inc., together with its subsidiaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators. The company also offers MIS silicon chip capacitors and transceivers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
